Active — Not RecruitingPhase 3

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

United States658 participantsStarted 2021-05-27

Plain-language summary

The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Not a woman of childbearing potential (WOCBP) OR
✓. A WOCBP who agrees to follow the contraceptive guidance during the open-label extension period and for at least 20 weeks after the final dose of investigational medicinal product (IMP)

What they're measuring

Percentage of participants with treatment-emergent adverse events (TEAEs) during the study

Timeframe: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196)

Trial details

NCT IDNCT04901195

SponsorUCB Biopharma SRL

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-07-28

View on ClinicalTrials.gov More Hidradenitis Suppurativa trials